Categories: HealthcareNews

Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Live Conference Call and Webcast at 8:30 a.m. ET

PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Friday, March 22, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a business update.

Event Agile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conference Call
Date Friday, March 22, 2024
Time 8:30 a.m. ET / 5:30 a.m. PT
   

A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics website at https://ir.agiletherapeutics.com/events-and-presentations. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call.

About Agile Therapeutics, Inc.

Agile Therapeutics is a women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website and LinkedIn account.

CONTACT: Contact:
Matt Riley

Head of Investor Relations & Corporate Communications

mriley@agiletherapeutics.com

Staff

Recent Posts

Artificial Intelligence (A.I.) in Life Science: New Survey of 408 Researchers Reveals Split Sentiment, Surging Adoption, and Rising Trust Barriers

ARLINGTON, Va., June 20, 2025 /PRNewswire/ -- New survey data from 408 global scientists and researchers…

3 hours ago

Salem Dentist (Smiles Of Salem) Stands with Veterans in National Push for Better Healthcare Protections

This Fourth of July, Dr. Harbpinder Shevchenko, DMD of Smiles of Salem is going beyond…

3 hours ago

American Textile Company’s Centennial Gala Marks 100 Years of Success!

Pittsburgh Event Celebrates Employees, Partners and a Commitment to Growth DUQUESNE, Pa., June 20, 2025…

3 hours ago

Nihar Gala Launches CareIQ, a Pioneering Remote Patient Monitoring Company, and Releases Inspiring New Book “The Strength to Endure”

SEAFORD, Del., June 20, 2025 /PRNewswire/ -- Acclaimed physician, entrepreneur, and visionary healthcare leader Nihar Gala…

3 hours ago

LevelJump Announces 2024 Financial Results

Toronto, Ontario--(Newsfile Corp. - June 20, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the…

4 hours ago